POSIFLEX-TECHNOLOGY
25.6.2024 08:53:31 CEST | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, today announced its latest mobile POS tablet offering - the Opera MT-6200 Series, which explores mobility and efficiency with sleek, lightweight yet semi-rugged designs. It supports Android 13 with GMS Certification or Windows 11 IoT OS, available in both x86 and RISC variants. With screen sizes of 8" and 10.1", the series features dockability with a USB Type-C connector, allowing for fast power charging. Complemented by a variety of POS accessories to enhance functionality, they are designed to meet the demands of the mobile economy across various industries. This includes retail stores, hospitality, logistics, inventory/warehouse management, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624392969/en/
The Posiflex Opera MT-6200 Series Mobile POS Tablet (Photo: Business Wire)
Superior Durability for Tough Applications
Leveraging Posiflex's cutting-edge engineering excellence, the Opera MT-6200 Series achieves a harmonious balance between the conflicting demands of tablets. It combines a lightweight and thin design with high-performance computing and semi-rugged durability. Equipped with a Corning Gorilla III touch screen, a PCAP multi-touch TFT LCD with 300nits brightness. The tablet is ideal for heavy use in various environments with ease. To ensure durability, the series incorporates semi-rugged designs, including IP54 water and dust resistance. It can withstand drops from 1 meter (1.2 meters with a protective case) and features a unique anti-slip design, providing a secure grip during handheld use. These elements collectively make the Opera MT-6200 Series resilient against the challenges of daily use.
Efficient USB Type-C for Fast Charging
Fast power charging and power efficiency are also essential to support the superior mobility of POS tablets. The Opera MT-6200 Series features an IPX7 waterproof USB Type-C connector for docking and rapid power charging. This feature enhances the overall user experience, providing convenience and efficiency for on-the-go professionals in various business environments. In particular, the smart docking station has a special bracket for protection and convenient charging, but when the tablet is in a rubber protective case, it can be docked directly to the charger without removing the case.
Flexible Functions for Customizable User Experience
In addition to a built-in 2D scanner and NFC module, Opera MT-6200 Series tablets offer programmable buttons on both sides of the screen bezel for customizable functionality, allowing customization for your specific applications. Opera MT-6200 series leads the way with seamless connectivity, supporting WiFi 5/6 and Bluetooth 5.0/5.2, ensuring a superior and efficient user experience.
Wide Range of Accessories to Extend Functionality and Maximize Convenience
As one of the manufacturers in the world capable of producing a complete range of POS terminals and peripherals from a single source, Posiflex offers a wide range of optional accessories including fingerprint reader, MSR, shoulder strap, protective case with rotatable handheld strap, touch pen and more. The smart docking station is also equipped with a variety of I/O ports to extend the functions for stationary operations - all to maximize flexibility, user value and convenience.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Software-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624392969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom